## Scottish Medicines Consortium

Providing advice about the status of all newly licensed medicines



www.scottishmedicines.org.uk

Delta House (8th floor) 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Angela Timoney FRPharmS

## **Statement of Advice:**

## dexamethasone (Ozurdex ®) 0.7 mg intravitreal implant (No: 751/11) Allergan

09 December 2011

**ADVICE**: in the absence of a submission from the holder of the marketing authorisation

**dexamethasone (Ozurdex** ®) **0.7 mg intravitreal implant** is not recommended for use within NHS Scotland.

**Indication:** Treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

## Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman, Scottish Medicines Consortium